Immunologic Factors: all 3,292 studies that test it

Page 12 of 33. Open to participants first (386), then studies with results posted, then the rest; newest registration first within each.

• Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/IICompletedNCT00789685Phase 1/2Results posted
• Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological CancerCompletedNCT00787761Phase 2Results posted
• Hematopoietic Stem Cell Transplant in Devic's DiseaseCompletedNCT00787722Phase 1/2Results posted
• Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin LymphomaCompletedNCT00784927Phase 2Results posted
• Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell LymphomasCompletedNCT00783367Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line TherapyCompletedNCT00774345Phase 3Results posted
• Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITPCompletedNCT00774202Phase 2/3Results posted
• Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00772915Phase 2Results posted
• Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZLTerminatedNCT00772668Not applicableResults posted
• Randomized Trial for Mixed Acute RejectionCompletedNCT00771875Phase 2Results posted
• Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant RecipientsCompletedNCT00771745Phase 4Results posted
• Alemtuzumab + Rituximab Consolidation in CLLTerminatedNCT00771602Phase 2Results posted
• CC-4047 (Pomalidomide) for Graft vs. Host DiseaseCompletedNCT00770757Phase 2Results posted
• A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)CompletedNCT00770562Phase 3Results posted
• S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin LymphomaCompletedNCT00770224Phase 2Results posted
• Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin LymphomaCompletedNCT00765245Phase 2Results posted
• Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's LymphomaCompletedNCT00764517Phase 2Results posted
• Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)CompletedNCT00759798Phase 2Results posted
• Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic LeukemiaCompletedNCT00759603Phase 2Results posted
• Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)TerminatedNCT00751296Phase 2Results posted
• Treatment of Multiple System Atrophy Using Intravenous ImmunoglobulinsCompletedNCT00750867Phase 2Results posted
• A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple MyelomaCompletedNCT00742560Phase 2Results posted
• A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" TrialCompletedNCT00737529Phase 2Results posted
• Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHLCompletedNCT00732498Phase 2Results posted
• Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to TherapyCompletedNCT00727415Phase 1/2Results posted
• Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And RituximabCompletedNCT00724971Phase 1Results posted
• Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple MyelomaCompletedNCT00724568Phase 1/2Results posted
• Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin LymphomaCompletedNCT00720876Phase 2Results posted
• Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell TransplantationTerminatedNCT00720629Phase 2Results posted
• Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other DiseaseTerminatedNCT00719849Phase 2Results posted
• A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)CompletedNCT00719472Phase 3Results posted
• A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)CompletedNCT00718549Phase 3Results posted
• Lenalidomide for Advanced Hepatocellular Cancer:A Phase II TrialCompletedNCT00717756Phase 2Results posted
• Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue SarcomaTerminatedNCT00717522Phase 2Results posted
• Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell LymphomaCompletedNCT00712582Phase 2Results posted
• Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell LymphomaCompletedNCT00711828Phase 2Results posted
• Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCTCompletedNCT00709592Phase 2Results posted
• A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) PatientsTerminatedNCT00699842Phase 1/2Results posted
• Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic PurpuraCompletedNCT00699140Phase 3Results posted
• Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin LymphomaCompletedNCT00695786Phase 2Results posted
• Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin LymphomaCompletedNCT00695409Phase 2Results posted
• The Effect of Rituximab on the Development of Anti-Donor AntibodiesCompletedNCT00695097Not applicableResults posted
• Interferon-alpha Lozenges for Prevention of Relapse in Hepatitis CCompletedNCT00695019Phase 2Results posted
• Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance TherapyCompletedNCT00691704Phase 2Results posted
• Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin LymphomaTerminatedNCT00691652Phase 1/2Results posted
• Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantCompletedNCT00691015Phase 2Results posted
• Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell LymphomaCompletedNCT00690560Phase 2Results posted
• Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple MyelomaCompletedNCT00689936Phase 3Results posted
• Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00687674Phase 1Results posted
• Lenalidomide (Revlimid) for the Treatment of Refractory Cancer PainTerminatedNCT00684242Phase 2Results posted
• Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00679367Phase 2Results posted
• Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1CompletedNCT00678886Phase 3Results posted
• Open Label Study of Alefacept Injections to Patients With Moderate to Severe PsoriasisCompletedNCT00678470Not applicableResults posted
• A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple SclerosisCompletedNCT00676715Phase 2Results posted
• Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)TerminatedNCT00675441Phase 2Results posted
• Study of Natalizumab in Relapsed/Refractory Multiple MyelomaTerminatedNCT00675428Phase 1/2Results posted
• A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate TherapyTerminatedNCT00673920Phase 3Results posted
• Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell LymphomaCompletedNCT00670358Phase 1/2Results posted
• Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/LymphomaCompletedNCT00669877Phase 2Results posted
• CC-4047 in Treating Patients With MyelofibrosisCompletedNCT00669578Phase 1/2Results posted
• Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00669318Phase 2Results posted
• Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor NeuropathyCompletedNCT00666263Phase 3Results posted
• Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined SignificanceTerminatedNCT00665652Phase 2Results posted
• Ph2 Gem/Nov/Rituxan Rel/Ref MantleCellCompletedNCT00656084Phase 2Results posted
• A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's LymphomaTerminatedNCT00655668Phase 2Results posted
• Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type PsoriasisCompletedNCT00655564Phase 4Results posted
• Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin LymphomaCompletedNCT00654732Phase 2Results posted
• Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC PatientsCompletedNCT00654186Phase 2Results posted
• Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCTCompletedNCT00648037Not applicableResults posted
• Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00643097Phase 2Results posted
• Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)CompletedNCT00642954Phase 1Results posted
• A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular LymphomaCompletedNCT00636792Phase 2Results posted
• Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple MyelomaTerminatedNCT00635024Phase 2Results posted
• A Phase I/II Trial of VR-CHOP in Lymphoma PatientsCompletedNCT00634179Phase 1/2Results posted
• Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)CompletedNCT00633945Not applicableResults posted
• Rituximab, Lenalidomide, and Bortezomib in Mantle Cell LymphomaCompletedNCT00633594Phase 1/2Results posted
• Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual DiseaseCompletedNCT00632359Phase 2Results posted
• Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)CompletedNCT00629798Phase 2Results posted
• A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)TerminatedNCT00626197Phase 3Results posted
• Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic LeukemiaTerminatedNCT00625729Phase 1/2Results posted
• Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate VaccineCompletedNCT00624819Phase 3Results posted
• A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple MyelomaCompletedNCT00622336Phase 3Results posted
• Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell TransplantCompletedNCT00619684Phase 2Results posted
• Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell TransplantTerminatedNCT00617929Phase 2Results posted
• A Study to Assess the Efficacy and Safety of Alefacept in Kidney Transplant RecipientsCompletedNCT00617604Phase 2Results posted
• Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)CompletedNCT00617591Phase 2Results posted
• Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After RituximabCompletedNCT00609869Phase 2Results posted
• Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate MofetilTerminatedNCT00608517Not applicableResults posted
• Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple MyelomaCompletedNCT00603447Phase 1Results posted
• Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00602836Phase 2Results posted
• Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT00602641Phase 3Results posted
• Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic LeukemiaCompletedNCT00602459Phase 2Results posted
• Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell LymphomaCompletedNCT00601718Phase 1/2Results posted
• Trial of Rituximab for Graves' OphthalmopathyCompletedNCT00595335Phase 2/3Results posted
• Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System LymphomaCompletedNCT00594815Not applicableResults posted
• Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic TransplantationTerminatedNCT00593645Phase 2Results posted
• Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined SignificanceTerminatedNCT00588822Phase 2Results posted
• Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHLCompletedNCT00588094Phase 2Results posted
• Intravenous Immune Globulin (IVIG) Treatment Protocol in Kidney Transplant PatientsTerminatedNCT00586716Not applicableResults posted
• Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm InfantsCompletedNCT00586612Phase 3Results posted

← Immunologic Factors overview